spacer
home > ebr > spring 2018 > therapy at work
PUBLICATIONS
European Biopharmaceutical Review

Therapy at Work

EBR: What is cell therapy?

Dr Daniel Shelly: The use of living human cells as therapeutic treatments can replace lost functionality or introduce a novel function (eg chimeric antigen receptor T-cells to attack tumours). Cell therapies are often classified as either autologous or allogeneic. Autologous cells are obtained from, transformed, and given back to the individual patient, whereas allogeneic cells are sourced from a single donor, grown in large numbers, transformed, and given to multiple patients.

Numerous methods of transformation exist such as using peptides to activate immune cells, using viral vectors to introduce new genetic functions, or gene editing (CRISPR-Cas9) to enhance cellular function. The cell therapy industry is currently at a turning point, driven by significant advances on many fronts, such as a significant amount of product approvals with several more to come, a regulatory recognition of the unique nature of the sector, a financial maturity and investor interest, and finally a general public awareness and interest.

Despite these advances, the sector still needs to optimise several key areas such as manufacture, storage (cryopreservation), formulation, and distribution of such products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Shelly is Director of business development at Albumedix, responsible for business development and out-licensing of the companyís core technologies and recombinant albumin products for manufacture, stabilisation, and formulation of small molecule, peptide, protein, viral, and cell therapeutics. He spent 10 years in cell culture, vaccine, and gene therapy clinical development and manufacturing. Daniel has authored several peerreviewed articles and book chapters and is an Adjunct Professor in the University of Cincinnati, US, clinical masterís programme, teaching biologics discovery and biotechnology management. He has degrees from Lehigh University (BA), US, The College of William and Mary (MA), US, Florida State (PhD), US, and the University of Cincinnati (MBA), US. Daniel did his post doctorate at the University of California, US, winning the APS Physiological Genomics Fellowship and a National Institutes of Health National Research Service Award.
spacer
Dr Daniel Shelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

[NoŠin, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement